Skip to main
  1. Stocks
  2. Neurocrine Biosciences
  3. Forecast
NBIX

Neurocrine Biosciences (NBIX) Stock Forecast & Price Target

Neurocrine Biosciences (NBIX) Analyst Ratings

Based on 22 analyst ratings
Buy
Strong Buy 45%
Buy 41%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Neurocrine Biosciences is benefiting from robust commercial execution, with 3Q26 revenue of $1.12 billion rising 41% year over year as Ingrezza, Crenessity, and VYKAT XR all beat expectations and drove non-GAAP diluted EPS of $3.3. Ingrezza remains the anchor, as ~$801 million in sales, record prescriptions, and a raised FY26 guide to $2.9 billion-$2.925 billion support another year of growth despite expected pricing pressure, while 2027 access looks at least as strong as 2026 and volume should still outpace net price erosion. Crenessity’s ~$211 million quarter, >$800 million annualized run rate, and low penetration in classic CAH leave substantial runway, and the pipeline adds further upside through multiple 2027 readouts in psychiatry, VMAT2, and CAH.

Bears say

Neurocrine Biosciences is exposed to meaningful downside if Ingrezza and Crenessity grow more slowly than expected, if Vykat XR also underperforms, or if new competitors and pricing pressure erode market share and pricing power. The outlook is further weakened by the possibility of real-world safety signals, changing physician preferences versus Austedo, and regulatory or clinical setbacks that could delay or derail pipeline assets. In a downside scenario, those pressures could reduce estimates materially, with one DCF-based valuation cited at $85, while partnership disruptions and failure of ongoing trials add additional execution risk.

Neurocrine Biosciences (NBIX) has been analyzed by 22 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 41% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Neurocrine Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Neurocrine Biosciences (NBIX) Analyst Forecast & Price Prediction

Get the latest Neurocrine Biosciences (NBIX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Neurocrine Biosciences (NBIX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Neurocrine Biosciences (NBIX) Forecast

Analysts have given Neurocrine Biosciences (NBIX) a Buy based on their latest research and market trends.

According to 22 analysts, Neurocrine Biosciences (NBIX) has a Buy consensus rating as of Nov 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $202.59, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $202.59, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Neurocrine Biosciences (NBIX)


Neurocrine Biosciences (NBIX) Analyst Forecast & Price Prediction

Get the latest Neurocrine Biosciences (NBIX) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in Neurocrine Biosciences (NBIX)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover NBIX stock data and trends